Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

SHOPPING: Give yourself the gift of improved sense of self with the once-a-day treatment that contains ingredients to support ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Healthcare companies were flat as traders rotated into higher-risk sectors. Shares of Hims & Hers rallied after the online pharmacy said it would continue selling compounded versions of glucagon-like ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...